FrancophonIA/ELRC3.0 huggingface dataset:
English: Discard the used pen and the cap.
Croatian: Zbrinite iskorištenu brizgalicu i kapicu.
English: Used barrel
Croatian: Iskorištena igla
English: In patients failing two or more prophylactic pharmacotherapies the proportion was 41.3% for 140 mg and 35.6% for 70 mg versus 14.2% for placebo with an odds ratio of 4.2 (95% CI: 2.2, 7.9) and 3.5 (95% CI: 1.8, 6.6), respectively.
Croatian: U bolesnika kod kojih su prethodne dvije ili više profilaktičkih farmakoterapija bile neuspješne, udio je bio 41,3% za 140 mg i 35,6% za 70 mg naspram 14,2% za placebo uz omjere izgleda od 4,2 (95% CI: 2,2; 7,9) odnosno 3,5 (95% CI: 1,8;
English: For the 140 mg dose you must inject the contents of either one 140 mg single-use syringe or two 70 mg single-use syringes, one after the other.
Croatian: Za dozu od 140 mg morate ubrizgati sadržaj ili jedne brizgalice za jednokratnu uporabu od 140 mg ili dviju brizgalica za jednokratnu uporabu od 70 mg, jednu iza druge.
English: CARTON OF UNIT PACK - pre-filled pen
Croatian: KUTIJA JEDINIČNOG PAKIRANJA - napunjena brizgalica
English: Sodium hydroxide (for pH adjustment) Glacial acetic acid
Croatian: 6.1 Popis pomoćnih tvari saharoza polisorbat 80 natrijev hidroksid (za prilagodbu pH) ledena acetatna kiselina voda za injekcije
English: Do not use the pen if the cap is missing or is not securely attached.
Croatian: Ne upotrebljavajte brizgalicu ako nema kapicu ili ako kapica nije sigurno pričvršćena.
English: Thigh
Croatian: Plunger
English: There was a higher proportion of patients in the erenumab group who achieved at least a 50% reduction of MMD compared to placebo (34.6% for 140 mg, 36.4% for 70 mg versus 17.7% for placebo), with an odds ratio of 2.5 (95% CI: 1.3, 4.9) and 2.7 (95% CI: 1.4, 5.2), respectively.
Croatian: Viši je bio udio bolesnika u erenumab skupini koji su postigli smanjenje DMM-a od najmanje 50% u usporedbi s placebom (34,6% za 140 mg, 36,4% za 70 mg naspram 17,7% za placebo), uz omjer izgleda od 2,5 (95% CI: 1,3; 4,9) odnosno 2,7 (95% CI: 1,4; 5,2).
English: In patients failing two or more prophylactic pharmacotherapies the treatment difference was -4.3 days (95% CI: -5.8; -2.8) between 140 mg and placebo and -2.7 days (95% CI: -4.2, -1.2) between 70 mg and placebo.
Croatian: U bolesnika kod kojih su dvije ili više profilaktičkih farmakoterapija bile neuspješne, razlika u liječenju je bila -4,3 dana (95% CI: -5,8; -2,8) između erenumaba 140 mg i placeba te -2,7 dana (95% CI: -4.2; -1.2) između erenumaba 70 mg i placeba.
English: Method of administration
Croatian: Metoda štipanja
English: There was also a higher proportion of subjects treated with erenumab who achieved at least 50% reduction of MMD compared to placebo (39.7% for 140 mg and 38.6% for 70 mg, with an odds ratio of 3.1 [95% CI: 1.7, 5.5] and 2.9 [95% CI: 1.6, 5.3], respectively).
Croatian: Također, veći je bio udio ispitanika liječenih erenumabom koji su postigli smanjenje DMM-a od najmanje 50% u usporedbi s placebom (39,7% za 140 mg i 38,6% za 70 mg, uz omjer izgleda od 3,1 [95% CI: 1,7; 5,5] odnosno 2,9 [95% CI: 1,6; 5,3]).
English: White cap on
Croatian: Bijela kapica postavljena
English: To avoid discomfort at the site of injection, the pre-filled syringe(s) should be left to stand at room temperature (up to 25°C) for at least 30 minutes before injecting.
Croatian: Da bi se izbjegla nelagoda na mjestu primjene injekcije, napunjenu štrcaljku(e) potrebno je ostaviti da odstoji na sobnoj temperaturi (do 25°C) najmanje 30 minuta prije ubrizgavanja.
English: Aimovig 140 mg injection erenumab
Croatian: Aimovig 140 mg injekcija erenumab s.c.
English: - Aimovig 140 mg solution for injection in pre-filled syringe contains 140 mg erenumab.
Croatian: - Aimovig 140 mg otopina za injekciju u napunjenoj brizgalici sadrži 140 mg erenumaba.
English: - Aimovig 70 mg solution for injection in pre-filled syringe contains 70 mg erenumab.
Croatian: - Aimovig 70 mg otopina za injekciju u napunjenoj brizgalici sadrži 70 mg erenumaba.
English: CARTON OF UNIT PACK - pre-filled syringe
Croatian: KUTIJA JEDINIČNOG PAKIRANJA - napunjena štrcaljka
English: Do not place your finger on the plunger while inserting the needle.
Croatian: Ne postavljajte prst na klip dok ubadate iglu.
English: Grey needle cap off
Croatian: Siva kapica igle postavljena
English: MIDAS (modified) total Mean changec (95% CI)
Croatian: MIDAS (modificiran) ukupno
English: Grey start button
Croatian: Siva tipka za aktivaciju
English: Aimovig 70 mg solution for injection in pre-filled syringe Aimovig 140 mg solution for injection in pre-filled syringe erenumab
Croatian: Aimovig 70 mg otopina za injekciju u napunjenoj brizgalici Aimovig 140 mg otopina za injekciju u napunjenoj brizgalici erenumab
English: To avoid discomfort at the site of injection, leave the syringe(s) at room temperature for at least 30 minutes before injecting.
Croatian: Da biste izbjegli nelagodu na mjestu primjene injekcije, ostavite štrcaljku(e) na sobnoj temperaturi najmanje 30 minuta prije ubrizgavanja.
English: In patients failing one or more prophylactic pharmacotherapies the treatment difference for the reduction of MMD observed between erenumab 140 mg and placebo was -2.5 (95% CI: -3.4, -1.7) and between erenumab 70 mg and placebo -2.0 (95% CI: -2.8, -1.2).
Croatian: U bolesnika u kojih je jedna ili više profilaktičkih farmakoterapija bila neuspješna, razlika u liječenju za smanjenje DMM-a između erenumaba 140 mg i placeba bila je -2,5 (95% CI: -3,4; -1,7) te između erenumaba 70 mg i placeba -2,0 (95% CI: -2,8; -1,2).
English: One pre-filled syringe contains 140 mg erenumab.
Croatian: Jedna napunjena štrcaljka sadrži 140 mg erenumaba.
English: Aimovig 70 mg injection erenumab
Croatian: Aimovig 70 mg injekcija erenumab s.c.
English: Keep the syringe(s) in the outer carton in order to protect from light.
Croatian: Brizgalicu(e) čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
English: One pre-filled syringe contains 70 mg erenumab.
Croatian: Jedna napunjena štrcaljka sadrži 70 mg erenumaba.
English: In patients failing one or more prophylactic pharmacotherapies the treatment difference for the reduction of monthly migraine days (MMD) observed between erenumab 140 mg and placebo was -3.3 days (95% CI: -4.6, -2.1) and between erenumab 70 mg and placebo -2.5 days (95% CI: -3.8, -1.2).
Croatian: U bolesnika kod kojih su prethodne jedna ili više profilaktičkih farmakoterapija za migrenu bile neuspješne, razlika u liječenju za smanjenje DMM-a opažena između erenumaba 140 mg i placeba bila je -3,3 dana (95% CI: -4,6; -2,1) te između erenumaba 70 mg i placeba -2,5 dana (95% CI: -3,8; -1,2).
English: There was also a higher proportion of subjects treated with erenumab who achieved at least 50% reduction of MMD compared to placebo in the patients failing one or more prophylactic pharmacotherapies (40.8% for 140 mg, 34.7% for 70 mg versus 17.3% for placebo), with an odds ratio of 3.3 (95% CI: 2.0, 5.5) for 140 mg and 2.6 (95% CI: 1.6, 4.5) for 70 mg.
Croatian: Također, veći je bio udio ispitanika liječenih erenumabom koji su postigli smanjenje DMM-a od najmanje 50% u usporedbi s placebom u skupini bolesnika kod kojih je jedna ili više profilaktičkih farmakoterapija bila neuspješna (40,8% za 140 mg, 34,7% za 70 mg naspram 17,3% za placebo), uz omjer izgleda od 3,3 (95% CI:
English: Aimovig 140 mg solution for injection in pre-filled syringe
Croatian: Aimovig 140 mg otopina za injekciju u napunjenoj brizgalici
English: To avoid discomfort at the site of injection, leave the pen(s) at room temperature for at least 30 minutes before injecting.
Croatian: Da biste izbjegli nelagodu na mjestu primjene injekcije, ostavite brizgalicu(e) na sobnoj temperaturi najmanje 30 minuta prije ubrizgavanja.
English: Aimovig 70 mg solution for injection in pre-filled syringe erenumab
Croatian: Aimovig 70 mg otopina za injekciju u napunjenoj brizgalici erenumab
English: Aimovig 140 mg solution for injection in pre-filled syringe erenumab
Croatian: Aimovig 140 mg otopina za injekciju u napunjenoj brizgalici erenumab
English: Cotton balls or gauze pads Adhesive plasters Sharps disposal container
Croatian: Na čistu, dobro osvijetljenu radnu površinu postavite: novu štrcaljku(e) alkoholne maramice pamučne vatice ili gazu flastere spremnik za odlaganje oštrih predmeta
English: Each pre-filled syringe contains 70 mg erenumab.
Croatian: Jedna napunjena brizgalica sadrži 70 mg erenumaba.
English: Skin and subcutaneous tissue disorders Pruritus a
Croatian: Poremećaji kože i potkožnog tkiva
English: Aimovig 70 mg solution for injection in pre-filled syringe
Croatian: Aimovig 70 mg otopina za injekciju u napunjenoj brizgalici
English: responders
Croatian: Doziranje
English: Orange cap on
Croatian: Narančasta kapica postavljena
English: Mean changec (95% CI)
Croatian: Srednja promjenac (95% CI)
English: Each pre-filled syringe contains 140 mg erenumab.
Croatian: Jedna napunjena brizgalica sadrži 140 mg erenumaba.
English: Keep the pre-filled pens in the outer carton in order to protect from light.
Croatian: Čuvati napunjene brizgalice u vanjskom pakiranju radi zaštite od svjetlosti.
English: Barrel
Croatian: Bedro
English: Renal impairment / hepatic impairment
Croatian: Oštećenje bubrega / oštećenje jetre
English: The injection site should be changed for each injection.
Croatian: Mjesto injekcije treba se mijenjati za svaku injekciju.
English: This summary was last updated in 09-2016.
Croatian: Ovaj sažetak je posljednji put ažuriran u 09.2016.
English: The full EPAR for NovoRapid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek NovoRapid nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This allows it to start acting faster than human insulin.
Croatian: To mu omogućuje da djeluje brže od ljudskog inzulina.
English: What is NovoRapid and what is it used for?
Croatian: Što je NovoRapid i za što se koristi?
English: NovoRapid can be used in pregnant women.
Croatian: NovoRapid se može primjenjivati u trudnica.
English: The usual dose is between 0.5 and 1.0 units per kilogram body weight per day.
Croatian: Uobičajena doza iznosi od 0,5 do 1,0 jedinica po kilogramu tjelesne težine po danu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for NovoRapid on 7 September 1999.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek NovoRapid na snazi u Europskoj uniji od 7. rujna 1999.
English: Other information about NovoRapid
Croatian: Ostale informacije o lijeku NovoRapid
English: NovoRapid is usually given immediately before a meal, although it may be given after a meal if necessary.
Croatian: Lijek NovoRapid obično se primjenjuje neposredno prije obroka, no može se primjenjivati i nakon obroka ako je potrebno.
English: What measures are being taken to ensure the safe and effective use of NovoRapid?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka NovoRapid?
English: Why is NovoRapid approved?
Croatian: Zašto je NovoRapid odobren?
English: NovoRapid is used to treat adults, adolescents and children over one year old who have diabetes.
Croatian: NovoRapid se koristi za liječenje odraslih osoba, adolescenata i djece starije od godinu dana koji boluju od dijabetesa.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that NovoRapid's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka NovoRapid nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: This is a summary of the European public assessment report (EPAR) for NovoRapid.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek NovoRapid.
English: When it is used with meals, 50 to 70% of the insulin requirement may be provided by NovoRapid and the remainder by an intermediate or long-acting insulin.
Croatian: Ako se koristi uz obroke, 50 % do 70 % potrebe za inzulinom može se zadovoljiti lijekom NovoRapid, a preostali dio srednjedugodjelujućim ili dugodjelujućim inzulinom.
English: NovoRapid reduced HbA1c levels by 0.12% and by 0.15% more than human insulin did after six months.
Croatian: Lijek NovoRapid snizio je razine HbA1c za 0,12 % te za 0,15 % više od ljudskog inzulina nakon šest mjeseci primjene.
English: By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
Croatian: Kontrolom razine glukoze u krvi smanjuju se simptomi i komplikacije dijabetesa.
English: What are the risks associated with NovoRapid?
Croatian: Koji su rizici povezani s lijekom NovoRapid?
English: It is not intended to provide practical advice on how to use NovoRapid.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka NovoRapid.
English: Patients can inject themselves under the skin with NovoRapid if they have been trained appropriately.
Croatian: Bolesnici mogu sami primjenjivati potkožne injekcije lijeka NovoRapid ako su prošli odgovarajuću obuku.
English: NovoRapid can also be used in a pump system for continuous insulin infusion under the skin or alternatively, it can be given into a vein but only by a doctor or a nurse.
Croatian: Lijek NovoRapid također se može koristiti u pumpi za kontinuiranu potkožnu infuziju inzulina ili se alternativno može primjenjivati u venu, no to smije obavljati samo liječnik ili medicinska sestra.
English: The patient's blood glucose (sugar) should be tested regularly to find the lowest effective dose.
Croatian: Potrebno je redovito mjeriti razinu glukoze (šećera) u krvi bolesnika kako bi se otkrila najniža djelotvorna doza.
English: NovoRapid insulin aspart
Croatian: EPAR, sažetak za javnost aspart inzulin
English: NovoRapid is a replacement insulin that is very similar to the insulin made by the body but is absorbed faster by the body.
Croatian: NovoRapid je zamjenski inzulin vrlo sličan inzulinu koji proizvodi tijelo, ali ga tijelo brže apsorbira.
English: The most common side effect with NovoRapid (seen in between 1 and 10 patients in 100) is hypoglycaemia (low blood glucose levels).
Croatian: Najčešća nuspojava pri primjeni lijeka NovoRapid (zabilježena u 1 do 10 na 100 osoba) je hipoglikemija (niske razine glukoze u krvi).
English: NovoRapid is normally used in combination with an intermediate- or long-acting insulin given at least once a day.
Croatian: Obično se koristi u kombinaciji sa srednjedugodjelujućim ili dugodjelujućim inzulinom koji se daje barem jednom na dan.
English: NovoRapid is a solution for injection available in vials, cartridges (PenFill and PumpCart) and pre-filled pens (FlexPen, FlexTouch and InnoLet) and can only be obtained with a prescription.
Croatian: NovoRapid je otopina za injekciju dostupna u bočicama, ulošcima (PenFill i PumpCart) i napunjenim brizgalicama (FlexPen, FlexTouch i InnoLet) te se izdaje samo na recept.
English: Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose.
Croatian: Dijabetes je bolest kod koje tijelo ne proizvodi dovoljno inzulina za kontrolu razine glukoze u krvi.
English: The safety has been found to be the same as human insulin when compared in two studies involving 349 pregnancies in women with type 1 or gestational diabetes (diabetes caused by pregnancy).
Croatian: Ustanovljeno je da je lijek NovoRapid jednako siguran kao ljudski inzulin u dvama ispitivanjima kojima je obuhvaćeno 349 trudnica s dijabetesom tipa 1 ili gestacijskim dijabetesom (dijabetesom uzrokovanim trudnoćom).
English: NovoRapid gave almost identical results to human insulin in two studies involving 1,954 patients with type 1 diabetes (when the pancreas cannot produce insulin) and in one study involving 182 patients with type 2 diabetes (when the body is unable to use insulin effectively).
Croatian: Rezultati lijeka NovoRapid bili su gotovo identični rezultatima ljudskog inzulina u dvama glavnim ispitivanjima na 1 954 bolesnika s dijabetesom tipa 1 (kod kojeg gušterača ne može stvarati inzulin) i jednom na 182 bolesnika s dijabetesom tipa 2 (kod kojeg tijelo ne može koristiti inzulin na učinkovit način).
English: The replacement insulin works in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Croatian: Zamjenski inzulin djeluje na isti način kao i prirodno proizveden inzulin i pomaže glukozi da uđe u stanice iz krvi.
English: It is given by injection under the skin in the abdominal (belly) wall, the thigh, the upper arm, the shoulder or the buttock.
Croatian: Primjenjuje se kao potkožna injekcija u abdominalnu (trbušnu) stijenku, bedro, nadlakticu, rame ili stražnjicu.
English: The studies compared NovoRapid with human insulin by measuring the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Croatian: U ispitivanjima lijek NovoRapid uspoređen je s ljudskim inzulinom mjerenjem razine tvari naziva glikozilirani hemoglobin (HbA1c) u krvi, koja pokazuje koliko se dobro kontrolira razina glukoze u krvi.
English: What benefits of NovoRapid have been shown in studies?
Croatian: Koje su koristi lijeka NovoRapid dokazane u ispitivanjima?
English: For more information about treatment with NovoRapid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom NovoRapid pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: How is NovoRapid used?
Croatian: Kako se NovoRapid koristi?
English: For practical information about using NovoRapid, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka NovoRapid pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: NovoRapid has also given comparable results when studied in children from one year of age.
Croatian: Rezultati lijeka NovoRapid također su se pokazali sličnima u ispitivanjima provedenima na djeci u dobi od jedne godine i starije dobi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoRapid have been included in the summary of product characteristics and the package leaflet.
Croatian: U sažetku opisa svojstava lijeka i uputi o lijeku za lijek NovoRapid nalaze se preporuke i mjere opreza za sigurnu i učinkovitu primjenu lijeka NovoRapid kojih se zdravstveni radnici i bolesnici trebaju pridržavati.
English: How does NovoRapid work?
Croatian: Kako djeluje NovoRapid?
English: It contains the active substance insulin aspart, a rapid-acting insulin.
Croatian: Ovaj lijek sadrži djelatnu tvar, brzodjelujući inzulin, tzv. aspart inzulin.
English: For the full list of all side effects and restrictions with NovoRapid, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka NovoRapid kao i ograničenja potražite u uputi o lijeku.
English: Date of first authorisation: 10 April 2014 Date of last renewal: 12 December 2018
Croatian: Datum posljednje obnove odobrenja: 12. prosinca 2018.
English: If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).
Croatian: Ako ste alergični na pregabalin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: If you are an elderly patient (over 65 years of age), you should take Pregabalin Pfizer normally except if you have problems with your kidneys.
Croatian: Ako ste bolesnik u starijoj dobi (iznad 65 godina), lijek Pregabalin Pfizer trebate uzimati normalno, osim ako imate problema s bubrezima.
English: It is important to take your Pregabalin Pfizer capsules regularly at the same time each day.
Croatian: Važno je da Pregabalin Pfizer kapsule uzimate redovito, svakoga dana u isto vrijeme.
English: Pregabalin Pfizer should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).
Croatian: Pregabalin Pfizer se ne smije primjenjivati tijekom trudnoće osim ako to nije neophodno (ako korist liječenja za majku jasno nadilazi mogući rizik za plod).
English: Pregabalin Pfizer and certain other medicines may influence each other (interaction).
Croatian: Pregabalin Pfizer i neki drugi lijekovi mogu djelovati jedni na druge (interakcija).
English: • Your doctor will tell you to take Pregabalin Pfizer either twice or three times a day.
Croatian: • Liječnik će Vam reći da uzmete lijek Pregabalin Pfizer dva puta ili tri puta na dan.
English: These symptoms may occur more commonly or severely if you have been taking Pregabalin Pfizer for a longer period of time.
Croatian: Ti simptomi mogu biti češći ili ozbiljniji ako ste lijek Pregabalin Pfizer uzimali dulje vrijeme.
English: Take your box or bottle of Pregabalin Pfizer capsules with you.
Croatian: Uzmite sa sobom kutiju ili bocu Pregabalin Pfizer kapsula.
English: It is advised not to drink alcohol while taking Pregabalin Pfizer.
Croatian: Preporučuje se da ne pijete alkohol dok uzimate lijek Pregabalin Pfizer.
English: The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Pfizer is taken together with medicines containing:
Croatian: Omaglica, pospanost i smanjenje koncentracije mogu se pojačati ako se Pregabalin Pfizer uzima zajedno s lijekovima koji sadrže:
English: Continue taking Pregabalin Pfizer until your doctor tells you to stop.
Croatian: Nastavite uzimati lijek Pregabalin Pfizer dok Vam liječnik ne kaže da prestanete.
English: In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by Week 1 and was maintained throughout the treatment period.
Croatian: U kliničkim ispitivanjima u trajanju do 12 tjedana je i kod periferne i kod centralne neuropatske boli smanjenje boli opaženo u Prvom tjednu liječenja i održalo se tijekom cijelog trajanja liječenja.
English: What Pregabalin Pfizer is and what it is used for What you need to know before you take Pregabalin Pfizer How to take Pregabalin Pfizer Possible side effects
Croatian: Što je Pregabalin Pfizer i za što se koristi Što morate znati prije nego počnete uzimati Pregabalin Pfizer Kako uzimati Pregabalin Pfizer Moguće nuspojave
English: • Pregabalin Pfizer may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
Croatian: • Pregabalin Pfizer može uzrokovati zamagljen vid, gubitak vida ili druge promjene vida, od kojih su mnoge privremene.
English: If you have the impression that the effect of Pregabalin Pfizer is too strong or too weak, talk to your doctor or pharmacist.
Croatian: Ako Vam se čini da je djelovanje lijeka Pregabalin Pfizer prejako ili preslabo, porazgovarajte sa svojim liječnikom ili ljekarnikom.
English: • A small number of people being treated with anti-epileptics such as Pregabalin Pfizer have had thoughts of harming or killing themselves.
Croatian: • Mali broj ljudi koji se liječe antiepileptičkim lijekovima kao što je Pregabalin Pfizer razmišljali su o samoozljeđivanju ili samoubojstvu.
English: The safety and efficacy of Pregabalin Pfizer in children below the age of 12 years and in adolescents (12-17 years of age) have not been established.
Croatian: Sigurnost i djelotvornost lijeka Pregabalin Pfizer u djece mlađe od 12 godina i adolescenata (1217 godina) nisu ustanovljene.
English: Pregabalin Pfizer is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.
Croatian: Pregabalin Pfizer nije namijenjena za samostalnu primjenu, nego se uvijek mora uzimati u kombinaciji s drugim antiepileptičkim lijekovima.
English: Pregabalin Pfizer should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor.
Croatian: Pregabalin Pfizer se ne smije uzimati tijekom trudnoće ili dojenja, osim ako Vam liječnik nije rekao drugačije.